An observational study in Gastric Cancer (GC), Colorectal Cancer and Pancreatic Cancer, sponsored by Medizinische Hochschule Brandenburg Theodor Fontane. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Medizinische Hochschule Brandenburg Theodor Fontane · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies in Stomach Neoplasms with a site in Germany — 26 open to participants now, 42 under way, 13 of them phase 3. Stomach Neoplasms · Germany.
Among the 162 studies in Stomach Neoplasms with a site in Germany, this one is the 22nd largest by enrollment of the 23 observational ones that give a count, is one of 11 that started in 2025, is one of 23 observational ones, and was the 160th registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →26 of the 162 studies in Stomach Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Germany
Ages 18–130
Akeso · Sites in Germany, United States, China and 1 more country
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 17 more countries
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 21 more countries
Ages 18+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 73 · Phase 3 46
First in 1999; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 278 across 792 observational studies indexed under Stomach Neoplasms.
Median enrollment 181 across the 138 interventional studies, 300 across the 23 observational. Of the 108 that completed or were terminated, 39 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 162 have an industry lead sponsor. The 10 most frequent:
Medizinische Hochschule Brandenburg Theodor Fontane is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Medizinische Hochschule Brandenburg Theodor Fontane has 3 studies filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
13 of the studies in Stomach Neoplasms with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06115629Phase 3University of Dublin, Trinity CollegeSurveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial | 2026-11 |
| NCT01924819Phase 3Australasian Gastro-Intestinal Trials GroupTrial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma | 2026-12-31 |
| NCT06532006Phase 3Shanghai Henlius BiotechA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | 2027-06-01 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT05993234Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyA Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) | 2026-12-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 162 studies in Stomach Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether a computer program can suggest cancer treatments that match expert recommendations for people with gastrointestinal cancer (cancer of the pancreas, stomach, or colon and rectum).
The main questions it aims to answer are:
Researchers will review existing medical records from people who have already been treated for these cancers. They will enter key clinical information into a computer program that uses artificial intelligence (AI). The program will generate treatment suggestions for each case.
Researchers will then compare these suggestions with:
This study will help researchers understand whether AI tools could support doctors in making cancer treatment decisions in the future.
Gastrointestinal cancers require complex treatment planning that often involves surgery, systemic therapy, and multidisciplinary coordination. Clinical decision-making is typically guided by evidence-based recommendations and discussed in multidisciplinary tumor boards. However, the increasing complexity of treatment strategies and guideline frameworks can make consistent and reproducible decision-making challenging in routine clinical practice.
Recent advances in artificial intelligence have enabled the development of large language models (LLMs) that can process structured clinical information and generate text-based recommendations. These systems may offer a scalable approach to support clinical workflows, but their ability to produce reliable and clinically appropriate treatment suggestions in oncology remains uncertain.
This study evaluates the performance of an LLM-based system in the context of gastrointestinal oncology using retrospectively collected clinical case data. Structured case summaries derived from routine clinical documentation are used as standardized input. The model generates treatment recommendations under controlled conditions, allowing systematic comparison with established clinical reference standards.
The analysis focuses on the level of agreement between model-generated recommendations and established decision-making frameworks. In addition, the study explores how model performance varies across different clinical scenarios, including varying levels of disease complexity. Particular attention is given to situations in which recommendations differ, in order to better understand potential limitations of the model and identify patterns that may be clinically relevant.
Furthermore, the study examines the consistency of model outputs when the same clinical information is processed multiple times. This provides insight into the stability and reproducibility of the system, which are important considerations for potential real-world use.
The findings of this study are intended to inform the potential role of LLM-based tools as supportive systems in clinical decision-making. The study does not evaluate clinical outcomes or patient benefit, but instead focuses on agreement with established standards and expert-driven decisions as an initial step in assessing feasibility and safety.
The study population consists of adult patients with gastrointestinal adenocarcinoma treated at a tertiary care academic center in the Federal State of Brandenburg, Germany. The population is derived from routine clinical practice and includes patients whose cases were evaluated in a multidisciplinary tumor board.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with pancreatic cancer
Other: Treatment recommendation according to official German cancer guideline · Other: Treatment recommendation of a LLM · Other: Treatment recommendation of a multidisciplinary tumor board
Patients with gastric cancer
Other: Treatment recommendation according to official German cancer guideline · Other: Treatment recommendation of a LLM · Other: Treatment recommendation of a multidisciplinary tumor board
Patients with colorectal cancer
Other: Treatment recommendation according to official German cancer guideline · Other: Treatment recommendation of a LLM · Other: Treatment recommendation of a multidisciplinary tumor board
Detailed treatment recommendation according to the official guideline of the Association of the Scientific Medical Societies in Germany (AWMF; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften),
Structured clinical case summaries were analyzed by a GPT-4-class large language model to generate treatment recommendations.
Detailed treatment recommendation according to the case-specific postoperative tumor board review.
Concordance with guideline-based management
Agreement between LLM-generated recommendations and AWMF guideline-supported treatment strategies
Time frame: At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Concordance with multidisciplinary tumor board decisions
Agreement between LLM-generated recommendations and tumor board treatment strategies
Time frame: At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Reproducibility of LLM recommendations across repeated runs
Structured clinical case vignettes were entered into ChatGPT using a standardized prompt template. To assess within-model reproducibility, each clinical vignette was analyzed in 3 independent model sessions performed on different days using identical clinical input.
Time frame: At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Characterization of discordant recommendations (e.g., overtreatment, undertreatment)
Overtreatment was defined as an LLM-generated recommendation exceeding the intensity of the reference recommendation. Undertreatment was defined as omission of a recommended treatment or recommendation of a less intensive strategy.
Time frame: At the time of multidisciplinary tumor board evaluation up to 4 weeks after surgery
Plan to share: No — Individual participant data will not be shared. The dataset consists of retrospective, pseudonymized clinical data from a single institution, and sharing is restricted due to data protection regulations and institutional policies.
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Jan 2026, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medizinische Hochschule Brandenburg Theodor Fontane